187 related articles for article (PubMed ID: 9869570)
1. Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis.
Miyazaki E; Miyazaki M; Chen JM; Chaisson RE; Bishai WR
Antimicrob Agents Chemother; 1999 Jan; 43(1):85-9. PubMed ID: 9869570
[TBL] [Abstract][Full Text] [Related]
2. Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis.
Yoshimatsu T; Nuermberger E; Tyagi S; Chaisson R; Bishai W; Grosset J
Antimicrob Agents Chemother; 2002 Jun; 46(6):1875-9. PubMed ID: 12019103
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis.
Ji B; Lounis N; Maslo C; Truffot-Pernot C; Bonnafous P; Grosset J
Antimicrob Agents Chemother; 1998 Aug; 42(8):2066-9. PubMed ID: 9687408
[TBL] [Abstract][Full Text] [Related]
4. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study.
Pletz MW; De Roux A; Roth A; Neumann KH; Mauch H; Lode H
Antimicrob Agents Chemother; 2004 Mar; 48(3):780-2. PubMed ID: 14982764
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice.
Lounis N; Bentoucha A; Truffot-Pernot C; Ji B; O'Brien RJ; Vernon A; Roscigno G; Grosset J
Antimicrob Agents Chemother; 2001 Dec; 45(12):3482-6. PubMed ID: 11709328
[TBL] [Abstract][Full Text] [Related]
6. Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis.
Rosenthal IM; Williams K; Tyagi S; Vernon AA; Peloquin CA; Bishai WR; Grosset JH; Nuermberger EL
Am J Respir Crit Care Med; 2005 Dec; 172(11):1457-62. PubMed ID: 16141439
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of moxifloxacin, a new 8-methoxyquinolone, for treatment of meningitis caused by a penicillin-resistant pneumococcus in rabbits.
Ostergaard C; Sørensen TK; Knudsen JD; Frimodt-Møller N
Antimicrob Agents Chemother; 1998 Jul; 42(7):1706-12. PubMed ID: 9661008
[TBL] [Abstract][Full Text] [Related]
8. Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance.
Entenza JM; Que YA; Vouillamoz J; Glauser MP; Moreillon P
Antimicrob Agents Chemother; 2001 Nov; 45(11):3076-83. PubMed ID: 11600359
[TBL] [Abstract][Full Text] [Related]
9. Bactericidal activity of moxifloxacin on exponential and stationary phase cultures of Mycobacterium tuberculosis.
Sulochana S; Mitchison DA; Kubendiren G; Venkatesan P; Paramasivan CN
J Chemother; 2009 Apr; 21(2):127-34. PubMed ID: 19423464
[TBL] [Abstract][Full Text] [Related]
10. In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis.
Almeida D; Nuermberger E; Tyagi S; Bishai WR; Grosset J
Antimicrob Agents Chemother; 2007 Dec; 51(12):4261-6. PubMed ID: 17938193
[TBL] [Abstract][Full Text] [Related]
11. Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model.
Nuermberger E; Tyagi S; Williams KN; Rosenthal I; Bishai WR; Grosset JH
Am J Respir Crit Care Med; 2005 Dec; 172(11):1452-6. PubMed ID: 16151038
[TBL] [Abstract][Full Text] [Related]
12. Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium.
Bermudez LE; Inderlied CB; Kolonoski P; Petrofsky M; Aralar P; Wu M; Young LS
Antimicrob Agents Chemother; 2001 Jan; 45(1):217-22. PubMed ID: 11120969
[TBL] [Abstract][Full Text] [Related]
13. Activity of moxifloxacin against mycobacteria.
Gillespie SH; Billington O
J Antimicrob Chemother; 1999 Sep; 44(3):393-5. PubMed ID: 10511409
[TBL] [Abstract][Full Text] [Related]
14. Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis.
Gillespie SH; Gosling RD; Uiso L; Sam NE; Kanduma EG; McHugh TD
J Antimicrob Chemother; 2005 Dec; 56(6):1169-71. PubMed ID: 16223939
[TBL] [Abstract][Full Text] [Related]
15. Which aminoglycoside or fluoroquinolone is more active against Mycobacterium tuberculosis in mice?
Lounis N; Ji B; Truffot-Pernot C; Grosset J
Antimicrob Agents Chemother; 1997 Mar; 41(3):607-10. PubMed ID: 9056001
[TBL] [Abstract][Full Text] [Related]
16. Effect of administration of moxifloxacin plus rifampin against Mycobacterium tuberculosis for 7 of 7 days versus 5 of 7 days in an in vitro pharmacodynamic system.
Drusano GL; Sgambati N; Eichas A; Brown D; Kulawy R; Louie A
mBio; 2011; 2(4):e00108-11. PubMed ID: 21750119
[TBL] [Abstract][Full Text] [Related]
17. Moxifloxacin and gatifloxacin in an acid model of persistent Mycobacterium tuberculosis.
Kubendiran G; Paramasivan CN; Sulochana S; Mitchison DA
J Chemother; 2006 Dec; 18(6):617-23. PubMed ID: 17267339
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis.
Alvirez-Freites EJ; Carter JL; Cynamon MH
Antimicrob Agents Chemother; 2002 Apr; 46(4):1022-5. PubMed ID: 11897584
[TBL] [Abstract][Full Text] [Related]
19. [Optimization of tuberculosis complex chemotherapy with the use of moxifloxacin].
Perel'man MI; Cokolova GB; Mozhokina GN; Lazareva IaV; Strekchev AIu; Elistratova NA
Antibiot Khimioter; 2004; 49(6):20-4. PubMed ID: 15628798
[TBL] [Abstract][Full Text] [Related]
20. Concentration-dependent killing of antibiotic-resistant pneumococci by the methoxyquinolone moxifloxacin.
Klugman KP; Capper T
J Antimicrob Chemother; 1997 Dec; 40(6):797-802. PubMed ID: 9462430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]